CLAIMS

1. An elongated oval-shaped compound cup tablet (1) comprising sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) in a total amount of about 60 to 99.8% (w/w) and an active pharmaceutical ingredient (API) in an amount of about 0.1-40 % (w/w) the tablet having

(a) a tablet height to width ratio of 0.9 or below, such as of about 0.05-0.9;

(b) a tablet height to cup depth ratio of above 4.3, such as of about 4.4-100;

(c) a minor major radius to width ratio of above 1.15, such as of about 1.16-100; and

(d) an index value of 0.67 or below, such as of about 0.05-0.55.

2. The tablet according to claim 1, wherein SNAC is present in a total amount of about 75-99 %, such as about 80-99 % or about 79-90 %in weight based on the total weight of the tablet.

3. The tablet according to any one of the preceding claims, wherein the API is present in about 0.1 to 14 % (w/w), such as in about 0.4 to 3 % (w/w) or 7-14% (w/w).

4. The tablet according to any one of the preceding claims, wherein the API is a peptide such as semaglutide.

5. The tablet according to any one of the preceding claims, wherein the tablet further comprises a lubricant.

6. The tablet according to any one of the preceding claims, wherein the lubricant is present in a total amount of about 0.1-7 % such as about 0.5-5 %, such as about 1-3 %, such as about 1.5-2.5% based on the total weight of the tablet.

7. The tablet according to any one of the preceding claims, wherein the lubricant is magnesium stearate.

8. The tablet according to any one of the preceding claims, wherein the tablet further comprises one or more pharmaceutically acceptable excipients.

9. The tablet according to any one of the preceding claims, wherein the tablet essentially consists of 84-97% SNAC, 0.1-14 % semaglutide and 1.5-3.5 % magnesium stearate, based on the total weight of the tablet.

10. The tablet according to any one of the preceding claims, wherein the total weight of the tablet is about 50 to 1200 mg.

11. The tablet according to any one of the preceding claims, wherein the total weight of the tablet about 290 to 390 mg or about 490 to 590 mg.

12. The tablet according to any one of the preceding claims, the tablet having

a) a major axis (3) of about 10.0-14.0 mm, such as about 12 mm;
b) a minor axis (4) of about 5.1-8.5 mm such as about 6.8 mm;
c) a side radius (6) of about 8.0-13.1 mm such as about 9.4 mm;
d) end radius of (5) about 1.8-3.0 mm such as 2.4 mm;
e) a cup depth (11) of about 0.7 to 1.5 mm, such as about 1.1 mm;
f) a major major radius (9) of above 19.3 mm, such as about 35 mm;
g) major minor radius (10) of below 16.0 mm, such as about 3.2 mm;
h) minor major radius (14) of above 6.6 mm, such as about 12.00; and/or
i) minor minor radius (15) of below 5.0 mm, such as about 2.5 mm.

13. The tablet according to any one of claims 1-11, the tablet having

a) a major axis (3) of about 11.7-16.5 mm, such as about 14.3 mm;
b) a minor axis (4) of about 6.0-10.0 mm such as about 8.1 mm;
c) a side radius (6) of about 9.4-15.4 mm such as about 11.0 mm;
d) end radius (5) of about 2.1-3.5 mm such as 2.8 mm;
e) a cup depth (11) of about 0.8-1.8 mm, such as about 1.2 mm;
f) a major major radius (9) of above 22.6 mm, such as about 40 mm;
g) major minor radius (10) of below 18.8 mm, such as about 3 mm;
h) minor major radius (14) of above 7.8 mm, such as about 12; and/or
i) minor minor radius (15) of below 5.9 mm, such as about 2.5 mm

14. A tablet according to any one of the preceding claims for use in medicine.

15. A tablet according to any one of the preceding claims for use in the treatment of diabetes and/or obesity.

16. Use of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) in a total amount of about 60 to 99.8% (w/w) and an active pharmaceutical ingredient (API) in an amount of about 0.1-40 % (w/w) in the manufacture of an elongated oval-shaped compound cup tablet for treating diabetes or obesity, the tablet having

(a) a tablet height to width ratio of 0.9 or below, such as of about 0.05-0.9;

(b) a tablet height to cup depth ratio of above 4.3, such as of about 4.4-100;

(c) a minor major radius to width ratio of above 1.15, such as of about 1.16-100; and

(d) an index value of 0.67 or below, such as of about 0.05-0.55.

5